MTOR and tuberous sclerosis: Given that the underlying abnormality in TSC is mTOR hyperactivity, the possibility of the mTOR pathway as a therapeutic strategy has been investigated as an alternative nonsurgical treatment of SEGA in patients with TSC [8].